Literature DB >> 3387169

Alveolar macrophage status in bronchopulmonary dysplasia.

A Clement1, K Chadelat, A Sardet, A Grimfeld, G Tournier.   

Abstract

The predominant inflammatory cell type within the alveolar structure in bronchopulmonary dysplasia (BPD) is the alveolar macrophage (AM). AM ability to release hydrogen peroxide, a way to evaluate the cell status, was studied in nine infants who developed clinical and radiological evidence of BPD, and was compared to those from infants without lung parenchymal disorders (n = 6). AM were collected by bronchoalveolar lavage which was done after the mechanical ventilation stage in the BPD group. The experiments were performed on unstimulated AM and on AM stimulated by phorbol myristate acetate. Results revealed that the amount of hydrogen peroxide accumulated in the culture medium was significantly enhanced in the BPD group, in both experimental conditions (p less than 0.01 and less than 0.001, respectively). Furthermore, improvement of patients treated with glucocorticoids was closely related to a reduction of the alveolitis with a decrease of AM ability to generate hydrogen peroxide. These data indicate that AM activation is a central component of alveolitis in BPD and that extracellular production of oxidants by stimulated AM may play a critical role in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3387169     DOI: 10.1203/00006450-198805000-00007

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  13 in total

1.  Omeprazole Attenuates Pulmonary Aryl Hydrocarbon Receptor Activation and Potentiates Hyperoxia-Induced Developmental Lung Injury in Newborn Mice.

Authors:  Binoy Shivanna; Shaojie Zhang; Ananddeep Patel; Weiwu Jiang; Lihua Wang; Stephen E Welty; Bhagavatula Moorthy
Journal:  Toxicol Sci       Date:  2015-08-13       Impact factor: 4.849

Review 2.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

3.  Elevated cytokine levels in tracheobronchial aspirate fluids from ventilator treated neonates with bronchopulmonary dysplasia.

Authors:  K Tullus; G W Noack; L G Burman; R Nilsson; B Wretlind; A Brauner
Journal:  Eur J Pediatr       Date:  1996-02       Impact factor: 3.183

4.  Inflammatory mediators and bronchopulmonary dysplasia.

Authors:  P Groneck; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-07       Impact factor: 5.747

Review 5.  The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia.

Authors:  P C Ng
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

6.  Functional deficiency of aryl hydrocarbon receptor augments oxygen toxicity-induced alveolar simplification in newborn mice.

Authors:  Binoy Shivanna; Wenyan Zhang; Weiwu Jiang; Stephen E Welty; Xanthi I Couroucli; Lihua Wang; Bhagavatula Moorthy
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-18       Impact factor: 4.219

7.  Tumour necrosis factor in the bronchoalveolar secretions of infants with the respiratory distress syndrome and the effect of dexamethasone treatment.

Authors:  S H Murch; T T MacDonald; C B Wood; K L Costeloe
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

8.  Bronchoalveolar lavage.

Authors:  A J Henderson
Journal:  Arch Dis Child       Date:  1994-03       Impact factor: 3.791

Review 9.  The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.

Authors:  H Clark; K Reid
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

10.  Consequences of early postnatal lipopolysaccharide exposure on developing lungs in mice.

Authors:  Amrit Kumar Shrestha; Matthew L Bettini; Renuka T Menon; Vashisht Y N Gopal; Shixia Huang; Dean P Edwards; Mohan Pammi; Roberto Barrios; Binoy Shivanna
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-11       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.